Progyny, Inc. (PGNY)
NASDAQ:PGNY
Want to see PGNY full AI Analyst Report?
PGNY Stock Chart & Stats
$18.12
$0.60(3.43%)
At close: 4:00 PM EST
$18.12
$0.60(3.43%)
Day’s Range― - ―
52-Week Range$16.10 - $28.75
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.72M
Market Cap
$2.23B
Enterprise Value$1.96B
Total Cash (Recent Filing)$226.15M
Total Debt (Recent Filing)$27.28M
Price to Earnings (P/E)35.2
Beta0.67
Next Earnings
Jul 30, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding78,332,370
10 Day Avg. Volume1,541,319
30 Day Avg. Volume1,720,755
Financial Highlights & Ratios
PEG Ratio2.48
Price to Book (P/B)4.24
Price to Sales (P/S)1.70
P/FCF Ratio11.41
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue1.51
Enterprise Value/Gross Profit6.27
Enterprise Value/Ebitda17.60
Forecast
1Y Price Target
$30.29Price Target Upside67.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.28
Revenue Forecast (FY)$1.38B
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageExtremely low debt-to-equity (~0.05) provides durable financial flexibility: supports ongoing product investment, opportunistic M&A or buybacks, and resilience through reimbursement or utilization cycles without stressing liquidity or requiring costly refinancing.
Re-accelerating Revenue Growth & UtilizationSustained top-line re-acceleration and above-average utilization reflect durable demand for employer fertility benefits and effective PMPM model. Higher utilization supports predictable revenue per covered life and underpins scalable economics as the client base expands.
Third-party Outcomes Validate Clinical And Cost BenefitsIndependent evidence of better clinical outcomes and lower per-baby costs strengthens Progyny's value proposition to employers, supporting long-term client retention, pricing leverage, and defensibility of the curated-network care model versus generic PBM or benefits alternatives.
Bears Say
Softer Free Cash Flow MomentumA marked slowdown in FCF growth and weaker cash conversion reduces available internal capital for reinvestment or future buybacks. If the trend persists, it could limit flexibility to fund platform expansion or absorb cyclical utilization dips without altering capital allocation.
Inconsistent Operating Margin ExpansionOperating margin compression signals reinvestment or cost pressures that may persist as management expands platform capabilities. If operating efficiency doesn't recover, profitability per member could stay constrained and pressure return-on-capital metrics over the medium term.
Client Transition & Eligibility Data Issues Raise Comparability RiskLarge client transitions and incomplete eligibility files create recurring headline volatility and forecasting uncertainty. Persistent data or onboarding gaps can hamper renewal visibility, distort growth comparisons, and force conservative guidance until remediation is fully implemented.
Progyny News
PGNY FAQ
What was Progyny, Inc.’s price range in the past 12 months?
Progyny, Inc. lowest stock price was $16.10 and its highest was $28.75 in the past 12 months.
What is Progyny, Inc.’s market cap?
Progyny, Inc.’s market cap is $2.23B.
When is Progyny, Inc.’s upcoming earnings report date?
Progyny, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 32 days.
How were Progyny, Inc.’s earnings last quarter?
Progyny, Inc. released its earnings results on May 07, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.256 by $0.034.
Is Progyny, Inc. overvalued?
According to Wall Street analysts Progyny, Inc.’s price is currently Undervalued.
Does Progyny, Inc. pay dividends?
Progyny, Inc. does not currently pay dividends.
What is Progyny, Inc.’s EPS estimate?
Progyny, Inc.’s EPS estimate is 0.34.
How many shares outstanding does Progyny, Inc. have?
Progyny, Inc. has 78,332,370 shares outstanding.
What happened to Progyny, Inc.’s price movement after its last earnings report?
Progyny, Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.256. Following the earnings report the stock price went up 23.8%.
Which hedge fund is a major shareholder of Progyny, Inc.?
Currently, no hedge funds are holding shares in PGNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.29 (67.14% Upside)
$30.29 (67.14% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 872.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $372.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.85%
12-Months-Change
Fundamentals
Return on Equity
13.34%
Trailing 12-Months
Asset Growth
-4.37%
Trailing 12-Months
Company Description
Progyny, Inc.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
PGNY Company Deck
PGNY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple operational and financial strengths: record Q1 revenue (at the high end of guidance), beats on net income/EPS/adjusted EBITDA, expanded gross margins, strong cash generation, completed a $200M buyback, and a de-risked renewal season with pipeline and early commitments pacing ahead of last year. Management raised full-year profitability guidance and maintained utilization and ART consumption assumptions. Challenges noted—administrative eligibility true-ups, ongoing investments (higher CapEx), comparability headwinds from a transition client, and conservative assumptions to guard against potential variability—are being actively managed and appear incremental rather than existential. Given the balance of robust financial results, validated clinical outcomes, and proactive mitigation of operational issues, the overall tone is constructive.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$30.29
▲(67.14% Upside)
Technical Analysis
Ownership Overview
2.82% Insiders
32.28% Mutual Funds
21.39% Other Institutional Investors
13.49% Public Companies and
Individual Investors